Tonix Pharmaceuticals announced the FDA has withdrawn its previously issued breakthrough therapy designation rescind letter and confirmed that the breakthrough therapy designation granted in December 2016 remains in effect for Tonmya for the treatment of posttraumatic stress disorder, or PTSD, which is in Phase 3 development. Tonix also announced that FDA has reversed itself and granted the company a meeting in June to present additional data to support continuing breakthrough therapy designation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.